Letrozole and norethisterone acetate in rectovaginal endometriosis

Non-randomised trial OA: bronze CC0 ⤵ 58 in-corpus citations
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated the efficacy and safety of letrozole and norethisterone acetate for treating rectovaginal endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This open-label prospective study evaluated the efficacy of letrozole (2.5 mg/day) combined with norethisterone acetate (2.5 mg/day) in the treatment of pain symptoms related to the presence of rectovaginal endometriosis. The treatment significantly and quickly decreased the intensity of symptoms, but pain recurred at 3-month follow-up; five women underwent surgery during the follow-up, and histologic examination of rectovaginal nodules revealed the presence of active endometriotic lesions.

My notes (saved in your browser only)

Condition tags

endometriosisbowel_endometriosis

MeSH descriptors

Aromatase Inhibitors Contraceptives, Oral, Synthetic Nitriles Rectal Diseases Triazoles Vaginal Diseases Administration, Oral Administration, Oral Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Drug Therapy, Combination Drug Therapy, Combination Female Female Humans Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (5)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-13T06:10:10.580696+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:04:17.981133+00:00
License: CC0 · commercial use OK